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Abstract
Double minutes (dmin), homogeneously staining regions, and ring chromosomes are vehicles of gene ampliﬁcation in
cancer. The underlying mechanism leading to their formation as well as their structure and function in acute myeloid
leukemia (AML) remain mysterious. We combined a range of high-resolution genomic methods to investigate the
architecture and expression pattern of amplicons involving chromosome band 8q24 in 23 cases of AML (AML-amp). This
revealed that different MYC-dmin architectures can coexist within the same leukemic cell population, indicating a step-wise
evolution rather than a single event origin, such as through chromothripsis. This was supported also by the analysis of the
chromothripsis criteria, that poorly matched the model in our samples. Furthermore, we found that dmin could evolve toward
ring chromosomes stabilized by neocentromeres. Surprisingly, ampliﬁed genes (mainly PVT1) frequently participated in
fusion transcripts lacking a corresponding DNA template. We also detected a signiﬁcant overexpression of the circular RNA
of PVT1 (circPVT1) in AML-amp cases versus AML with a normal karyotype. Our results show that 8q24 amplicons in
AML are surprisingly plastic DNA structures with an unexpected association to novel fusion transcripts and circular RNAs.
Introduction
Genomic ampliﬁcations in the form of double minutes
(dmin), homogeneously staining regions (hsr), and ring
chromosomes are frequent in cancer [1], although rare in
leukemia (<1% of cytogenetically abnormal hematological
malignancies) [2], and associated with an elderly age and
poor prognosis [3, 4]. Despite this clinical impact, the
underlying mechanisms of amplicon formation in acute
myeloid leukemia (AML) are unclear, and so are their
internal structures. Chromothripsis was described as a
potential mechanism involved in their genesis [5, 6].
However, the evidence we previously obtained in seven
tumor cell lines harboring 8q24 ampliﬁcations clearly
excluded this model in our samples [7], supporting alter-
native mechanisms such as the episome model [8–10].
Another crucial aspect of amplicons is their impact on the
transcriptome. Ampliﬁed cancer-associated genes are often
upregulated as a direct consequence of their copy number
(CN) gain [11]. Nevertheless, MYC, as well as other 8q24
co-ampliﬁed genes and long noncoding RNAs (lncRNAs)
(e.g., TRIB1, FAM84B, POU5F1B, PVT1, and TMEM75),
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represents a clear exception to this rule in myeloid malig-
nancies [9, 12, 13]. These ﬁndings suggest that none of
them could be considered as the real target for this type of
ampliﬁcation [14].
We investigated, at both genomic and transcriptomic
levels, a large cohort of AML cases harboring MYC
ampliﬁcations in the form of dmin, hsr, or ring chromo-
somes (AML-amp), in order to unravel the molecular
mechanisms as well as potential target genes behind their
genesis. To this end, we combined ﬂuorescence in situ
hybridization (FISH), immuno-FISH, PCR, single-
nucleotide polymorphism (SNP) array, whole-genome
sequencing (WGS), and RNA sequencing (RNA-seq).
Overall, our study provides a full overview of the 8q24
amplicon organization in dmin/hsr, as well as on ring
chromosomes, and sheds light on the extraordinarily high
transcriptome plasticity associated with AML-amp.
Materials and methods
Sample collection
This study included a total of 24 AML-amp cases (Sup-
plementary Table S1), two remission samples from cases
that were AML-amp at diagnosis, 29 AML cases with a
normal karyotype (AML-NK), 10 AML cases with chro-
mosomal abnormalities not involving chromosome 8, 23
AML cell lines with or without 8q24 gain, and one normal
peripheral blood (PB) and one bone marrow (BM) sample
as controls (Supplementary Table S1 and Supplementary
Methods).
Neocentromere detection on ring chromosomes
AML-amp cases MLL_11929 and MLL_11933, as well as
two additional ones (#18 and #33) included in a previously
described cohort [9], with ring chromosomes were investi-
gated for the presence of neocentromere using FISH co-
hybridization experiments with an anti-CENP-C polyclonal
antibody (Cat. no. ABIN3072962 Eurogentec polyclonal
antibody service, Aachen, Germany) for functional cen-
tromeres [15], a pan-centromeric probe detecting all types
of alphoid subset sequences [16], and a BAC probe (RP11-
440N18) speciﬁc for MYC.
SNP array analysis
SNP array analysis was performed on 24 AML-amp cases
using the Affymetrix CytoScan HD platform (Affymetrix,
Santa Clara, CA, USA) following the manufacturer’s
protocol.
WGS and identiﬁcation of structural variants
WGS was performed on 23 AML-amp cases and two
remission samples (Supplementary Table S1) using the X
Ten platform (Illumina, San Diego, CA, USA), in a paired-
end 2× 150-cycle run, with a mean coverage of 30× per
sample. Candidate structural variants (SVs) were identiﬁed
using the DELLY software (v.0.7.1) [17] (details are pro-
vided in Supplementary Methods).
Chromothripsis analysis
To infer chromothripsis, WGS and SNP array proﬁles of
each case were evaluated according to published criteria
[18] (Supplementary Methods). We focused on the region
8q22.3–24.1 involved in the ampliﬁcations.
RNA-seq analysis
RNA-seq was performed on 20 AML-amp cases and two
remission samples (Supplementary Table S1). RNA-seq
libraries were prepared using the TruSeq RNA Sample
Preparation Kit v2 (Illumina) and sequenced on the
HiSeq2000 platform (Illumina) in paired-end 2× 101-cycle
runs (166Mreads/sample). To detect fusion transcripts
involving ampliﬁed genes, we used both ChimeraScan (CS)
[19] and FusionMap (FM) [20] (Supplementary Methods).
A custom bioinformatics pipeline was implemented to
combine SVs with chimeric transcript data and evaluate the
occurrence of post-transcriptional events in the genesis of
chimeras.
Differential gene expression analysis
To ascertain genes speciﬁcally expressed only in AML-
amp, six cases harboring 8q24 amplicons with no other
chromosomal changes were compared with six AML-NK
cases from The Cancer Genome Atlas (TCGA) (Supple-
mentary Table S1). The DESeq2 Bioconductor package
(v1.8.1) in R environment (v3.2.2) was used for Differential
gene expression analysis (DEA) of global gene expression
proﬁles in cases with/without 8q24 amplicons as well as for
explorations of 8q24 genes in the AML-amp data set
(Supplementary Methods). The ToppGene suite was used to
perform gene enrichment analysis (https://toppgene.cchmc.
org/).
Mutation analysis of 8q24-ampliﬁed genes
Genome and transcriptome data of 20 AML-amp cases
(Supplementary Table S1) were analyzed in parallel for
detection of non-synonymous single-nucleotide variants
(SNVs) and insertions/deletions (indels). Variants were
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called using GATK HaplotypeCaller [21] and VarScan2
(VarScan 2.3.7) [22] on RNA-seq and WGS data, respec-
tively, and then ﬁltered according to speciﬁc criteria (Sup-
plementary Methods). Pathway analysis was performed
using the MSigDB [23], GSEA [24], and DAVID [25] tools
to identify pathways associated with the mutated genes.
Assessment of circular PVT1 (circPVT1) expression
level
The expression of both linear and circPVT1 in eight AML-
amp cases, 12 AML cell lines, nine AML-NK cases, and in
one normal PB and one BM was analyzed by qPCR using
properly designed primers [26]. The nine AML-NK samples
were pooled and used as a calibrator; beta-2-microglobulin
(B2M) was used as a reference gene. Statistical signiﬁcance
was evaluated using the relative expression software tool
REST [27].
Results
8q24 dmin/hsr/rings amplify a 2246 kbp genomic
segment encompassing 11 lncRNAs and four coding
genes
By combining SNP array, WGS and FISH analyses, we
deﬁned the 8q24 amplicon organization in 23 AML-amp
cases. We identiﬁed a total of 373,585 raw SVs, of which
4630 were within the 8q24-ampliﬁed regions (Supplemen-
tary Table S2) and 84 of this subset (2%) were considered
as crucial for amplicon assembly, since they corresponded
to CN switches. Their validation by PCR and Sanger
sequencing revealed the occurrence of 30 microhomology
sequences, 36 anonymous insertions, and 18 blunt-end
joining events.
All AML-amp cases harbored ampliﬁed sequences
derived only from chromosome 8. The 8q24 ampliﬁcations
were mainly present on dmin or ring chromosomes, and
only rarely on hsr (Supplementary Table S3). The proximal
and distal breakpoints of the amplicons clustered in two
regions: the former at chr8:125,754,780–126,442,227 (687
kbp) in 20/23 (87%) cases and the latter at
chr8:130,690,866–130,950,708 (260 kbp) in 21/23 (91%)
cases. The minimal commonly ampliﬁed segment was
2,245,660 bp (Supplementary Figure S1). It comprises 15
RefSeq loci, including 11 lncRNAs (LINC00861,
LOC101927657, PCAT1, PCAT2, PRNCR1, CASC19,
CCAT1, CASC21, CASC8, CCAT2, and CASC11) and four
coding genes (TRIB1, FAM84B, POU5F1B, and MYC). In
addition, the lncRNAs PVT1 and CCDC26, just outside the
commonly ampliﬁed region, were ampliﬁed in 22/24 (92%)
cases.
8q24 amplicon structures suggest different levels of
molecular heterogeneity
All 23 cases investigated by WGS were classiﬁed according
to the heterogeneity of 8q24 amplicons. In 21 out of 23
cases, we identiﬁed a most represented “ancestral” ampli-
con, which was repeated in a head-to-tail fashion.
Eight cases (35%) displayed a single ancestral amplicon,
ranging from 3216 kbp to 5196 kbp, without remarkable
switches in their CN proﬁles. These cases were considered
to harbor non-heterogeneous amplicons (Fig. 1a, Supple-
mentary Figure S2a-g). A duplication SV joined the distal
and the proximal breakpoints of two adjacent ampliﬁed
segments in all cases except MLL_11932 and MLL_11937
(Supplementary Figure S2a-g).
The remaining 15 of the 23 cases showed different levels
of amplicon heterogeneity, which we dichotomized into low-
grade heterogeneity (LH) and high-grade heterogeneity
(HH). In total, 12/23 (52%) cases were classiﬁed as LH based
on the co-existence of heterogeneous amplicons related to,
and derived from, the ancestral ampliﬁed segment through
the occurrence of internal SVs (Fig. 1b, Supplementary
Figure S2h-r). Notably, all LH amplicons shared proximal
and distal breakpoints in the same patient (Fig. 1b).
Three (13%) of the 23 cases were considered HH
because they comprised distinct cell subpopulations carry-
ing amplicons with different internal structures arranged in
a noncontiguous, noncollinear array (Fig. 2, Supplementary
Figure S2s-t, Supplementary Methods).
Complex structures at the deletions junctions on
one chromosome 8 homolog
Of the 23 cases analyzed by SNP array, WGS, and FISH, 11
(48%) had heterozygous 8q24 deletions, corresponding to
the ampliﬁed regions on the dmin, ring chromosomes, and
hsr, on one of the chromosome 8 homologs. In four of the
11 cases, the deletion junctions were more complex than the
ones in the other deleted cases, by displaying inversions
with or without duplications, or reciprocal translocations at
the junctions.
Chromothripsis is not involved in 8q24 amplicon
genesis
The criteria deﬁned to infer chromothripsis were evaluated
across the 8q22.3–24.1 region in each AML-amp case
(Table 1). According to the criterion “clustering of break-
points”, we searched for 5–10 breakpoints within 50 kbp
genomic segments. This criterion was fulﬁlled in 22/23
(95.7%) cases (Supplementary Figure S3a). Regarding the
“regularity of oscillating copy number states”, we did not
observe more than 10 CN switches in 16/23 (69.6%) cases
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Fig. 1 Circular amplicons with no or low heterogeneity of structure.
Images show the internal structure of ampliﬁed segments in cases
MLL_11940 (as an example of a patient with no heterogeneous
amplicons joined by a duplication) (a) and MLL_12445 (as an
example of patient with two coexisting amplicons, one of which
derived from the other by a deletion) (b). For each patient: IGV plot of
WGS read depth at proximal and distal breakpoints of ancestral
amplicons; Circos plots (outer violet circular panel) and WGS read
depth (light blue inner panel) of recurrent amplicons, with internal
arrows indicating amplicon orientation and genes in dark gray, or in
orange if interrupted by a breakpoint (arrows represent the transcrip-
tional orientation). Inside the Circos plots, FISH pseudocolor images
showing co-localizing ampliﬁed probes, consistently colored as in the
Circos plot. Probes mapping respectively upstream and downstream of
the amplicons proximal and distal breakpoints are not ampliﬁed on
dmin and display signal only on normal chromosome 8. The red-
dashed semicircles in b represent sequence deletion on the ancestral
amplicon to obtain the secondary one
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(Supplementary Figure S3b). In the remaining seven
(30.4%) cases, the CN values ranged between more than
three CN states, thus exceeding the limit for chromothripsis.
Interestingly, we observed loss of heterozygosity in not-
deleted regions, indicating the occurrence of multi-step
rearrangement events (Supplementary Figure S3b).
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Concerning the “randomness of DNA segments order and
fragment joins”, the results were conﬂicting. On one hand,
the order of the breakpoints was not conserved, indicating
the presence of randomly joined chromosome fragments as
in chromothripsis (Supplementary Figure S3c). On the other
hand, there was not an equal distribution of rearrangement
types, as occurs in the step-wise rearrangement model
(Supplementary Figure S3d). Therefore, we considered this
criterion as not validated for the assessment of chromo-
thripsis in our samples. Finally, the criterion of “ability to
walk the derivative chromosome” was not fulﬁlled because
of the presence of nested ampliﬁed fragments (Supple-
mentary Figure S3e); this does not ﬁt the chromothripsis
model in which no “reuse” of rearranged fragments is
admitted. Taken together, the ﬁndings exclude the invol-
vement of chromothripsis in the genesis of 8q24 amplicons.
Neocentromeres stabilize tandemly ampliﬁed
sequences within ring chromosomes
FISH analyses of four AML-amp cases with amplicon-positive
chromosomes revealed that the the primary constrictions on
the ring chromosomes lacked alphoid satellite sequences but
were positive for CENP-C (Fig. 3), strongly indicating the
presence of functional ectopic centromeres, which are essential
for stabilizing ring chromosomes during cell divisions.
Ampliﬁed genes/lncRNAs are recurrently involved in
fusion transcripts
RNA-seq of AML-amp cases identiﬁed 12,468 and 58,032
raw chimeric transcripts by CS and FM, respectively,
among which 38 and 429 involved 8q24-ampliﬁed genes
(Supplementary Table S4A-B). Using RT-PCR and Sanger
sequencing, we validated 35 of these 8q24 fusion transcripts
(Table 2), 26 of which involved PVT1 as either a 5′ or 3′
partner (Supplementary Figure S4a). Notably, 15 chimeras
with PVT1 as a 5′ partner shared exactly the same break-
point position (at chr8:128,806,980). Other genes/lncRNAs
recurrently involved in chimeras were MYC, FAM49B,
RP11-89K10, CCDC26, CASC11, and CASC8. Of these,
MYC and CCDC26 each showed a recurrent breakpoint
position (at chr8:128,750,494 and chr8:130,365,226,
respectively) in three chimeras, where they are involved as
3′ partners. Remarkably, 15 out of the 35 (43%) validated
chimeras were generated by the fusion of two lncRNAs.
Some fusion transcripts were common to two or more cases,
were present as multiple transcript isoforms in the same
case or in different cases, or together with their reciprocal
fusion product (Table 2, Supplementary Table S4a).
In silico translation of the 5′ PVT1 chimeras predicted the
dysregulation of the protein product of their 3′ partner
transcripts due to promoter swapping or N-terminus trun-
cation (Table 2, Supplementary Figure S4b). Conversely, 3′
PVT1 fusions were predicted to display either a 3′
untranslated region substitution of their 5′ partner tran-
scripts or a C-terminus truncation of the encoded protein. A
truncation effect on the MTSS1 protein was also predicted
for 5′MTSS1/3′FAM49B fusion and its reciprocal 5′
FAM49B/3′MTSS1.
Interestingly, the 5′PVT1/3′CCDC26 chimera was the
only fusion we detected that was also in a panel of 23 AML
cell lines (Supplementary Table S4C-D). Similarly, neither
the two remission samples of AML-amp cases nor the
AML-NK cases harbored any of the 8q24 fusions detected
in AML-amp cases.
Fusion transcripts often do not correspond to
genomic rearrangements
By combining WGS and RNA-seq data, only 0.1% (12/
12,468) and 0.07% (43/58,032) of the chimeric transcripts
identiﬁed in our cohort by CS and FM, respectively, were
detected at the genomic level. After zooming into the 8q24
chromosome segment, their percentages increased to 10.5%
(4/38) and 7.2% (31/428) by CS and FM, respectively.
These results suggest that the chimeric transcripts might be
mostly generated by post-transcriptional events (Supple-
mentary Table S4E). Moreover, our AML-amp cases
showed a statistically signiﬁcant higher number of 8q24
chimeras (mean 2.5 and 41.8 for CS and FM tools,
respectively) as compared to AML-NK control cases from
Fig. 2 Circular amplicons with high heterogeneity of structure. Images
show the internal organization and inferred evolutionary path of
amplicons in case 07B60, as an example of a patient with clonal
amplicon heterogeneity. The ancestral amplicon (07B60a, occurring in
the 26.4% (14/53) of cells), at the top of the ﬁgure, underwent two
independent rearrangement types, indicated as R6/R7 (middle left) or
R8 (middle right), originating the secondary amplicons 07B60b (bot-
tom left), observed in 73.6% (39/53) of cells, and 07B60c (bottom
right), without cell speciﬁcity at the FISH level. Circos plots (in violet)
represent all reconstructed ampliﬁed structures, with WGS read depth
(in light blue) and genes in dark gray, or in orange if interrupted by a
breakpoint (arrows represent the transcriptional orientation). Red-
dashed semicircles and purple curved lines respectively represent
sequence deletions and newly originated SVs labeled by appropriated
codes. Inside the 07B60a Circos plot, IGV plots of WGS read depth at
amplicon borders (bottom) and FISH pseudocolor images show co-
ampliﬁcation of delimiting amplicons proximal and distal breakpoints
(top). The red-dashed semicircles represent sequence deletions on the
ancestral amplicon to obtain both secondary ones. It is worth noting
that dmin-harboring 07B60a amplicons showed the co-localization of
all four indicated probes in the FISH experiments, contrary to those
containing 07B60b, which displayed signals only for the green and
blue probes, indicating a cell speciﬁcity of sequence ampliﬁcations
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TCGA [0.7 and 0.2 for CS and FM, respectively; U-test p
= 0.004792 (CS) and p= 1.116e−08 (FM)] (Supplemen-
tary Figure S4c-d).
AML-amp cases show a peculiar gene signature
associated with 8q24 chimeras
To investigate genes differentially expressed in AML-amp
cases, we performed a DEA by comparing six AML-amp cases
with six AML-NK samples from TCGA. Globally, we found
853 differentially expressed genes among which only two
mapped in the 8q24 region, namely, MTSS1 and RP11-
532M24.1 (Supplementary Table S5A). Gene enrichment
analysis showed that differentially expressed genes upregulated
in AML-amp versus control cases displayed functions related to
myeloid cell differentiation and homeostasis as well as chro-
matin assembly, nucleosome organization, histone methylation,
and gene silencing (Supplementary Table S5B-C).
Unsupervised hierarchical clustering analysis of all the
8q24 genes in the 20 AML-amp cases revealed a high level
of sample heterogeneity and clearly showed the presence of
two major subgroups, denoted Group A (5 cases) and Group
B (15 cases) (Fig. 4a). To ascertain the reason(s) for these
two groups, we compared age, gender, cytogenetic features,
and number of chimeras and genomic breakpoints involving
the 8q24 region between the groups. This revealed a sig-
niﬁcant difference in the number of chimeras and genomic
breakpoints (Fig. 4b). In addition, there was a positive
correlation between the number of genomic breakpoints and
the number of chimeras (identiﬁed by both CS and FM),
indicating a close association between genomic complexity
and transcriptomic plasticity of fusion transcripts (Fig. 4b-
c). The DEA of Group A versus Group B samples identiﬁed
nine differentially expressed genes mapping in the 8q24
region, which were upregulated in Group A (Supplementary
Table S5D). Among these, we found the lncRNA PVT1 and
the coding NSMCE2, which was the most signiﬁcantly
overexpressed gene in Group A (FDR= 10−18).
Mutations in AML-amp cases affect genes involved
in cell division and chromatin modiﬁcations
We identiﬁed 467 SNVs/indels affecting 432 genes (Sup-
plementary Table S6A), of which 19 were involved in two
or more samples (Supplementary Table S6B), and 95
grouped into 31 gene families (Supplementary Table S6C).
The most frequently mutated genes in the AML-amp cases
were TET2 (50% of the cases), DNMT3A (25%), TP53
(15%), and KMT2C (alias MLL3, 15%). Pathway analysis
grouped the 432 mutated genes into four main pathways:
cell cycle, TP53 downstream pathway, chromatin mod-
iﬁcations, and kinases (Supplementary Table S6D). These
results indicate that most of the mutated genes are involved
in cell division and epigenetic chromatin modiﬁcations.
Overexpression of circular PVT1 is associated with
high PVT1 CN ampliﬁcation
By qPCR, we demonstrated the strong upregulation of
circPVT1, generated by the circularization of PVT1 exon 2,
in AML-amp cases with amplicons including PVT1 com-
pared with AML-amp cases in which PVT1 was not
ampliﬁed (as 07B60) or AML-NK samples (Fig. 5a). In
AML cell lines, a slight upregulation of circPVT1 was
observed only in the two cell lines carrying more than ﬁve
copies of PVT1 (GF-D8 and KG-1). The PVT1 linear
transcript also showed an upregulation in PVT1-ampliﬁed
versus not ampliﬁed AML cases, but this difference dis-
appeared in AML cell lines where it was similarly expressed
regardless of PVT1 CN state (Fig. 5b).
Discussion
Our study focused on the comprehensive genomic and
transcriptomic characterization of 8q24 ampliﬁcations in
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AML. Overall, 65% of cases showed evidence of amplicon
heterogeneity. We previously observed the occurrence of
distinct cell subpopulations harboring different MYC
ampliﬁcations [9] and here conﬁrmed at the single-
nucleotide level.
Except for that of breakpoint clustering, we found that
none of the valuable chromothripsis criteria is veriﬁed in
our AML-amp cases. This is in accordance with our pre-
vious results on seven tumor cell lines with 8q24 amplicon
heterogeneity, which excluded the chromothripsis model as
involved in dmin/hsr genesis [7], in contrast with previous
literature [5, 6]. As a matter of fact, breakpoint clustering
might also result from events occurring at separate temporal
stages of the amplicon evolution [18]. Additionally, in 48%
of cases we observed deletions corresponding to the
ampliﬁed regions, not accompanied by any other rearran-
gement of the del(8) chromosome. Overall, these ﬁndings
suggested a multi-step pathway in dmin/hsr genesis, indi-
cating the episome model as the most reliable mechanism
underlying 8q24 dmin genesis in AML, as we already
proposed [9, 14].
8q24 ampliﬁcations also occurred as hsr and/or ring
chromosomes in some of our cases, conﬁrming that 8q24
amplicon architecture is shared among all these cytogenetic
structures [9, 28]. Interestingly, the discovery of neocen-
tromeres on ring chromosomes is an unprecedented result,
since ectopic centromeres emerging at chromosomes com-
posed by genomic ampliﬁcations were observed only in
well-differentiated liposarcomas [29] and lung cancer [30]
thus far. Centric ring chromosomes might represent an
evolutionary step of scattered acentric dmin as well as hsr
towards mitotic stabilization, providing an adaptive advan-
tage to leukemia cells harboring 8q24 ampliﬁcations. With
the availability of vital frozen cells, further investigation
into the genomic architectures of these neocentromeres will
help to better understand the evolutionary path of these
ampliﬁed sequences.
In this study, we focused on the identiﬁcation of chimeric
transcripts that originated from the 8q24-ampliﬁed genes.
To date, 8q24 ampliﬁcations have already been associated
with two fusion genes, namely PVT1-NSMCE2 and
BF104016-NSMCE2, found respectively in an AML case
and in the HL60 cell line [31]. Although the latter was not
identiﬁed by neither WGS [7] nor RNA-seq in our research,
we conﬁrmed the occurrence of the 5′PVT1/3′NSMCE2
fusion in our data set, along with its reciprocal 5′NSMCE2/
3′PVT1. The lncRNA PVT1 was described as a hotspot
target of genomic breakpoints in 8q24 ampliﬁcations [7, 29,
32–34]. Notably, gain of PVT1 expression is required for
high MYC protein levels in 8q24-ampliﬁed human cancer
cells [35]. Indeed, 26 out of 35 validated chimeras in our
AML-amp cases involved this lncRNA, and most of them
were recurrent in more cases and shared the sameTa
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breakpoint position. Many of the 8q24 chimeras we iden-
tiﬁed lacked genomic support and were associated with
dmin/hsr ampliﬁcation. Overall, the 8q24-ampliﬁed genes
were shown to be prone to originate chimeric transcripts,
often with not-ampliﬁed genes as partners. Our evidence
indicates that they might be originated by alternative
mechanisms to those based on genomic rearrangements.
Post-transcriptional events, such as trans-splicing or cis-
splicing between adjacent genes (cis-SAGe) [36–40], might
be an intriguing possibility that, however, needs further
experimental support. The potential oncogenic role of these
chimeras speciﬁcally accompanying 8q24 ampliﬁcations
will require further investigation.
Notably, we found that AML-amp cases with the highest
numbers of chimeras showed a peculiar 8q24 gene
expression signature characterized by the overexpression of
both PVT1 and NSMCE2, frequently found in our 8q24
chimeric transcripts. Unfortunately, such patient clustering
cannot be directly correlated to disease prognostic indica-
tions, since most of Group A patients were lost during
follow-up and lacked information about treatment and
overall survival. However, we could envisage a possible
prognostic implication given that Group A comprised three
out the ﬁve cases with complex karyotype and TP53
mutation/17p13 loss, which are notoriously associated with
a poorer outcome in AML [3]. Interestingly, NSMCE2,
which was overexpressed in Group A cases, is required for
DNA double-strand break repair and genomic integrity
maintenance [41, 42]. Its depletion was shown to sensitize
HeLa cells to DNA damage-induced apoptosis [43] sug-
gesting that, alternatively, its overexpression could make
tumor cells more resistant to the DNA damage induced by
their wide genomic rearrangements.
Moreover, we characterized the gene signature and
pathways speciﬁcally associated with the presence of 8q24
ampliﬁcations and found that the biological processes
affected by these dysregulated genes are related to cell
division and chromatin architecture. In particular, we
observed the upregulation of genes involved in myeloid and
erythroid cell development and differentiation, such as
CEBPA [44] and the key erythroid transcription factors
GATA1 [45], TAL1, and KLF1 [46]. According to the lit-
erature [47], KLF1 overexpression may be related to the
simultaneous presence of TET2 and DNMT3A mutations in
the two AML-amp cases investigated by our DEA.
DNMT3A and TP53 frequencies are in line with those
already reported in AML without 8q24 ampliﬁcations (30%
and 13%, respectively) [48]. Conversely, TET2 and KMT2C
mutations were more frequent in our cohort than in AML
without ampliﬁcations (23% and 0.5%, respectively) [48,
49], although with no dysregulation at the expression level
with respect to AML-NK samples. Interestingly, AML-amp
cases also showed upregulated genes involved in chromatin
assembly, nucleosome positioning, and H3K27 histone tri-
methylation, such as the replication-dependent histone
genes HIST1H1B, HIST1H1C, HIST1H1D, HIST1H1E,
HIST1H2BG, HIST1H2BF, HIST1H3E (all mapping within
the HIST1 cluster at 6p22-p21.3), and the replication inde-
pendent H1FX (3q21.3). Considering that histone H1 and
related linker histones are important for maintenance of
higher-order chromatin structure and gene expression reg-
ulation [50], their signiﬁcant upregulation in our cohort is of
interest and might shed light on the chromatin compaction
within dmin chromosomes.
Finally, the 8q24 commonly ampliﬁed genes, including
MYC, PVT1, and TRIB1, showed a variegated expression
pattern, consistent with previous reports [3, 9, 13, 14], thus
conﬁrming that they are not the real targets of this ampli-
ﬁcation type.
Remarkably, the transcriptional plasticity observed in our
AML-amp cohort also includes circRNAs originated by
back-splicing events [51], resistant to exonucleolytic
degradation [52], and accumulating at relatively high levels
within cells [47]. They have been proposed to act as
microRNA sponges, platforms for protein interactions,
transcriptional regulators of their linear counterparts, or, as
recently demonstrated, as protein translators [53–57].
Concerning genes in 8q24 region, circRNAs from MTSS1,
NSMCE2, FAM84B, POU5F1B, MYC, PVT1, and FAM49B
have already been cataloged in the CircInteractome data-
base (http://circinteractome.nia.nih.gov) [58]. circPVT1,
generated from exon 2 of PVT1, was found as highly
expressed in HeLa cervical cancer cells, human proliferat-
ing ﬁbroblasts [59], and gastric cancer cells often accom-
panied by 8q24 ampliﬁcations [53]. Notably, we found a
strict correlation between PVT1 CN gain and the upregu-
lation of this circPVT1 in both AML-amp cases and cell
lines. The NB4 cell line was an exception, since it did not
show overexpression of circPVT1 despite its gene ampliﬁ-
cation; nonetheless, here, as well as in case 07B60, we
cannot exclude the presence of additional PVT1 alterations
preventing the detection of the circRNA. circPVT1 was
proposed to act as a molecular sponge for tumor suppressor
microRNAs, such as those belonging to let-7 [59] or miR-
125 families [53]. Further investigation into its role in
AML-amp cases will therefore be required.
Fig. 4 Chimeric transcripts signiﬁcantly associated with a peculiar gene expression proﬁle at ampliﬁed regions and breakpoints. a Heatmap of
8q24 gene expression levels in our AML-amp cohort. b Box and Whisker plots illustrating differences in the number of breakpoints and chimeras
in 8q24 between Groups A and B. c Correlation analysis between the number of genomic breakpoints and chimeras in the 8q24 region identiﬁed by
CS (left) and FM (right)
Origin, evolution, and RNA targets of MYC amplicons... 2163
In summary, this work adds an important piece in the
puzzle of the genomic and transcriptomic impact of 8q24
ampliﬁcations in AML. The amplicon molecular hetero-
geneity and the deletion of the corresponding ampliﬁed
regions observed in the majority of cases ruled out chro-
mothripsis as a potential mechanism behind their origin.
Moreover, the neocentromeric seeding observed on ring
chromosomes, harboring tandemly ampliﬁed sequences,
would be engaged to stabilize collapsed acentric dmin,
providing a selective advantage to leukemia cells. Finally,
the ﬁnding of post-transcriptional chimeras and circRNAs
involving 8q24-ampliﬁed genes in AML-amp cases could
open new scenarios in the understanding of the biological
mechanisms behind MYC ampliﬁcations in leukemia.
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